- Company
- Myelofibrosis New Drug Inrebic
- by Eo, Yun-Ho Mar 10, 2023 05:50am
- Inrebic, a myelofibrosis treatment option born 10 years after Jakavi, is accelerating its steps toward insurance coverage. As a result of the coverage, BMS Pharmaceutical's myelofibrosis treatment Inrebic is in the process of drug price negotiations with the NHIS. Depending on the negotiation date, it is expected that it will be possible to
- Company
- Enbrel's share is 44% and Herceptin's share is 37%
- by Kim, Jin-Gu Mar 10, 2023 05:50am
- Mabthera, Avastin, and Humira similars also saw a sharp rise in market share new product addition effect. The share of biosimilar products in the domestic market is rapidly expanding. Enbrel biosimilars Etanercept increased its market share from 12% in 2018 to 44% last year. Herceptin similars also expanded from 9% to 37% during the same per
- Company
- Sales of Kisqali surge, Ibrance decline
- by Jung, Sae-Im Mar 9, 2023 06:00am
- The market for cyclin-dependent kinases (CDK) 4/6 inhibitors that are used to treat metastatic breast cancer have undergone drastic changes last year. Sales of Ibrance, which used to dominate the market, had faltered, while the latecomer Kisqali rapidly expanded its share in the market . According to the market research institution IQVIA
- Company
- Childhood dementia Tx Xenpozyme to soon land in KOR
- by Eo, Yun-Ho Mar 9, 2023 06:00am
- The first childhood dementia treatment is expected to be commercialized in Korea soon. According to industry sources, the Ministry of Food and Drug Safety is conducting the final review to approve Sanofi Genzyme’s treatment for acid sphingomyelinase deficiency (ASMD)m ‘Xenpozyme (olipudase alfa).’ Starting with Japan in March, the d
- Company
- Hemlibra is also effective for mild and secondary hemophilia
- by Kim, Jin-Gu Mar 9, 2023 06:00am
- JW Pharma announced on the 6th that Phase III clinical trials that proved the effects and safety of patients with type hemophilia have been published in the online edition of the Lancet Hematology 2023, an international journal. Hemlibra is a type A hemophilia disease caused by the deficiency of factor XIII. It is the only anti-antibody pat
- Company
- Becton Dickinson achieves a 90% customer satisfaction rate
- by Eo, Yun-Ho Mar 8, 2023 05:53am
- Becton Dickinson (BD Korea), a multinational medical device and equipment manufacturing company, achieved a customer satisfaction rate of 90%. The company conducted a customer satisfaction survey for domestic pharmaceutical and bio customers and announced the results on the 6th. The survey was conducted between January 9 and February 3 of thi
- Company
- Hemophilia A treatment market sales were 66 billion won
- by Kim, Jin-Gu Mar 8, 2023 05:53am
- Last year, sales of hemophilia A treatment in hospitals and clinics were tallied at 66 billion won. While existing major drugs are sluggish in hospitals and clinics, JW Pharmaceutical's Hemlibra, which recently joined the market, has risen in sales for two consecutive years, rising to No. 2 in the market. In the pharmaceutical industry, sale
- Company
- 'Vabysmo’s 4mth dosing interval may reduce patient burden'
- by Jung, Sae-Im Mar 8, 2023 05:53am
- A new drug for Neovascular (Wet) Age-Related Macular Degeneration (nAMD) that offers treatment effect with once every 4-month administration has landed in Korea. The new option is expected to greatly improve the convenience of administration in domestic patients whose number has been increasing with Korea’s aging population. Roche Korea hel
- Company
- Self-administered Kynteles lands at general hospitals
- by Eo, Yun-Ho Mar 8, 2023 05:52am
- The self-injectable formulation of the inflammatory bowel disease treatment ‘Kynteles’ can now be prescribed at general hospitals in Korea. According to industry sources, the subcutaneous injection formulation of Takeda Pharmaceuticals Korea’s Kynteles (vedolizumab) has passed the drug committee (DC) reviews in tertiary hospitals such
- Company
- Celltrion Healthcare published clinical result of Remsima SC
- by Hwang, Jin-joon Mar 8, 2023 05:51am
- Celltrion Healthcare announced on the 6th in Copenhagen, Denmark, that it was holding the '2023 European Crohn's Disease and Colitis Society (ECCO)' for four days from the 1st (local time), and 'Remsima SC' was held for the purpose of US approval. announced that it had unveiled a new global clinical trial of '. The first clinical trial is the
